This newslink doesn't exist or it was removed.
Go to Homempage.
Forbes USA Business November 29, 2022
Getty Images Key Takeaways Moderna became a household name for creating one of the first COVID-19 vaccines, helping to loosen up pandemic restrictions globally. Moderna’s stock went up during the pandemic for apparent reasons as countries were scrambling to purchase mass... + más
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
Moderna is suing Pfizer over its coronavirus vaccine | The Verge
The Advocate USA Crime October 10, 2022
vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine.Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed... + más
Moderna vs Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | Los Angeles Times
CNBC USA Health December 06, 2022
Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021.Dado Ruvic Reuters has rejected allegations made by rival that its Covid-19 vaccine is a copy, accusing the Boston biotech company of... + más
The Verge USA Health September 24, 2022
Moderna is suing Pfizer over its coronavirus vaccineModerna is suing Pfizer over its coronavirus vaccine / The company is filing patent infringement lawsuits against Pfizerp>span:first-child]:text-black text-blurple>By Aug 26, 2022, 12:37 PM UTC Share this story... + más
Moderna vs. Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | PennLive
Fox Business USA Business March 11, 2023
Check out what's clicking on FoxBusiness.com has revealed it will add to its workforce and its U.S. office footprint. In a put out Friday, Moderna said it will add about 2,000 new employees around the world.Moderna’s hiring efforts seemingly contrast with the reductions... + más
Moderna Stock Futures: Is COVID Vaccine Maker Moderna Poised To Pop Or Drop? | Forbes
Moderna’s Covid Boom Is Ending. Why the Outlook Isn’t All Grim. | MarketWatch
About iurex | Privacy Policy | Disclaimer |